Spyre Therapeutics Inc. (SYRE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.88B
Last updated: Nov 17, 2026 at 11:06 AM ET
Spyre Therapeutics Inc. (SYRE) Earnings: Report Dates and Results
Spyre Therapeutics (SYRE) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, Spyre Therapeutics reported EPS of -$0.94, below the -$0.79 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SYRE has an expected report date of Feb 17, 2027.
Earnings History
Of the 36 quarters below that had an estimate, SYRE beat 17 and missed 19. The widest gap in the table came in the quarter ended Dec 31, 2023, when EPS landed 419.23% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.94 | -$0.79 | -$1.53 - -$0.67 | -18.99% | Miss | N/A | 13 | 0 up, 1 down | Nov 3, 2026 | N/A |
| Jun 30, 2026 | -$0.36 | -$0.71 | -$1.00 - -$0.49 | +49.30% | Beat | N/A | 13 | 0 up, 2 down | Aug 4, 2026 | N/A |
| Mar 31, 2026 | -$0.74 | -$0.64 | -$0.81 - -$0.53 | -14.84% | Miss | N/A | 12 | 5 up, 3 down | May 5, 2026 | N/A |
| Dec 31, 2025 | -$0.74 | -$0.80 | -$1.91 - -$0.14 | +7.50% | Beat | N/A | 12 | 7 up, 3 down | Feb 19, 2026 | $90.49M |
| Sep 30, 2025 | -$0.15 | -$0.74 | -$0.99 - -$0.56 | +79.73% | Beat | N/A | 10 | 4 up, 3 down | Nov 4, 2025 | N/A |
| Jun 30, 2025 | -$0.49 | -$0.71 | -$0.83 - -$0.62 | +30.99% | Beat | N/A | 9 | 6 up, 0 down | Aug 5, 2025 | N/A |
| Mar 31, 2025 | -$0.60 | -$0.84 | -$0.97 - -$0.71 | +28.57% | Beat | N/A | 7 | N/A | May 8, 2025 | N/A |
| Dec 31, 2024 | -$0.81 | -$0.94 | -$1.14 - -$0.61 | +14.22% | Beat | N/A | 7 | 1 up, 0 down | Feb 27, 2025 | N/A |
| Sep 30, 2024 | -$1.36 | -$0.86 | -$1.05 - -$0.45 | -58.14% | Miss | N/A | 9 | 0 up, 0 down | Nov 7, 2024 | N/A |
| Jun 30, 2024 | -$0.86 | -$0.91 | -$1.21 - -$0.52 | +5.49% | Beat | N/A | 7 | 0 up, 0 down | Aug 7, 2024 | N/A |
| Mar 31, 2024 | -$1.20 | -$1.08 | N/A | -11.11% | Miss | N/A | 4 | 0 up, 0 down | May 9, 2024 | N/A |
| Dec 31, 2023 | -$4.05 | -$0.78 | -$1.15 - -$0.20 | -419.23% | Miss | N/A | 7 | 1 up, 0 down | Feb 29, 2024 | $1.04M |
| Sep 30, 2023 | -$9.34 | -$0.84 | N/A | N/A | N/A | N/A | N/A | N/A | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$56.75 | -$3.50 | N/A | N/A | N/A | N/A | N/A | N/A | Aug 11, 2023 | $688000 |
| Mar 31, 2023 | -$5.00 | -$4.37 | N/A | -14.42% | Miss | N/A | N/A | N/A | May 11, 2023 | $198000 |
| Dec 31, 2022 | -$5.00 | -$5.71 | N/A | +12.40% | Beat | N/A | N/A | N/A | Mar 30, 2023 | $168000 |
| Sep 30, 2022 | -$4.75 | -$5.87 | N/A | +19.08% | Beat | N/A | N/A | N/A | Dec 29, 2022 | $174000 |
| Jun 30, 2022 | -$6.75 | -$7.75 | N/A | +12.90% | Beat | N/A | N/A | N/A | Sep 28, 2022 | $625000 |
| Mar 31, 2022 | -$9.25 | -$8.54 | N/A | -8.38% | Miss | N/A | N/A | N/A | Jun 28, 2022 | $1.36M |
| Dec 31, 2021 | -$7.75 | -$7.63 | N/A | -1.57% | Miss | N/A | N/A | N/A | Mar 29, 2022 | $3.64M |
| Sep 30, 2021 | -$7.75 | -$7.34 | N/A | -5.59% | Miss | N/A | N/A | N/A | Dec 29, 2021 | $1.40M |
| Jun 30, 2021 | -$2.50 | -$4.30 | N/A | +41.86% | Beat | N/A | N/A | N/A | Sep 28, 2021 | $13.70M |
| Mar 31, 2021 | -$7.00 | -$3.49 | N/A | -100.57% | Miss | N/A | N/A | N/A | Jun 28, 2021 | N/A |
| Dec 31, 2020 | -$8.75 | -$8.57 | N/A | -2.07% | Miss | N/A | N/A | N/A | Mar 31, 2021 | N/A |
| Sep 30, 2020 | -$7.25 | -$9.97 | N/A | +27.28% | Beat | N/A | N/A | N/A | Nov 5, 2020 | N/A |
| Jun 30, 2020 | -$10.00 | -$10.76 | N/A | +7.06% | Beat | N/A | N/A | N/A | Aug 10, 2020 | N/A |
| Mar 31, 2020 | -$14.25 | -$16.41 | N/A | +13.16% | Beat | N/A | N/A | N/A | May 7, 2020 | N/A |
| Dec 31, 2019 | -$16.25 | -$16.75 | N/A | +2.99% | Beat | N/A | N/A | N/A | Feb 24, 2020 | N/A |
| Sep 30, 2019 | -$16.50 | -$13.31 | N/A | -23.97% | Miss | N/A | N/A | N/A | Dec 29, 2019 | N/A |
| Jun 30, 2019 | -$13.75 | -$12.08 | N/A | -13.82% | Miss | N/A | N/A | N/A | Aug 6, 2019 | N/A |
| Mar 31, 2019 | -$14.75 | -$13.80 | N/A | -6.88% | Miss | N/A | N/A | N/A | May 7, 2019 | N/A |
| Dec 31, 2018 | -$15.50 | -$0.37 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2019 | N/A |
| Sep 30, 2018 | -$13.50 | -$10.80 | N/A | -25.00% | Miss | N/A | N/A | N/A | Dec 29, 2018 | N/A |
| Jun 30, 2018 | -$11.50 | -$8.62 | N/A | -33.41% | Miss | N/A | N/A | N/A | Aug 9, 2018 | $2.38M |
| Mar 31, 2018 | -$12.25 | -$11.51 | N/A | -6.43% | Miss | N/A | N/A | N/A | May 8, 2018 | $1.51M |
| Dec 31, 2017 | -$9.75 | -$0.53 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2018 | $1.48M |
| Sep 30, 2017 | -$12.00 | -$13.77 | N/A | +12.85% | Beat | N/A | N/A | N/A | Dec 29, 2017 | $1.26M |
| Jun 30, 2017 | -$11.75 | -$12.00 | N/A | +2.08% | Beat | N/A | N/A | N/A | Aug 9, 2017 | $1.48M |
| Mar 31, 2017 | -$11.75 | -$11.70 | N/A | -0.43% | Miss | N/A | N/A | N/A | May 9, 2017 | $982000 |
| Dec 31, 2016 | -$0.56 | -$0.46 | N/A | -21.74% | Miss | N/A | N/A | N/A | Mar 31, 2017 | $1.25M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.98, after -$4.23 the year before. It was -$32.61 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.98 | N/A |
| Dec 31, 2024 | -$4.23 | N/A |
| Dec 31, 2023 | -$75.14 | N/A |
| Dec 31, 2022 | -$25.75 | N/A |
| Dec 31, 2021 | -$25.00 | N/A |
| Dec 31, 2020 | -$40.25 | N/A |
| Dec 31, 2019 | -$61.25 | N/A |
| Dec 31, 2018 | -$52.75 | N/A |
| Dec 31, 2017 | -$45.25 | N/A |
| Dec 31, 2016 | -$32.61 | N/A |
Frequently Asked Questions About SYRE
When is Spyre Therapeutics's next earnings date?
Spyre Therapeutics's next earnings report is expected for Feb 17, 2027.
Did SYRE beat earnings estimates last quarter?
No. Spyre Therapeutics reported EPS of -$0.94 for the quarter ended Sep 30, 2026, below the -$0.79 estimate by 18.99%.
What EPS do analysts expect from SYRE next quarter?
The consensus EPS estimate for Spyre Therapeutics for the quarter ending Dec 31, 2026 is -$0.93 from 17 analysts, with estimates from -$1.93 to -$0.62.
How often does SYRE beat earnings estimates?
Spyre Therapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +22.06%.
SYRE pages: Overview, Earnings, Forecast, Financials, Competitors